Prelude Therapeutics Incorporated (PRLD) Key Metrics
PRLD valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $260.2M
- Enterprise value
- $209.4M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 11.6
- Price / book
- 2.6 10-yr median 1.8
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.96
PRLD key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsPRLD valuation Price multiples at each fiscal year-end price.
PRLD returns How much profit the business earns on the capital it uses.
PRLD per-share figures Results divided by the shares outstanding at year-end.
PRLD financial health Debt, liquidity and how easily interest is covered.
PRLD efficiency & capital use Working capital cycle and where the cash goes.
PRLD valuation history
PRLD returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PRLD debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PRLD cash returned to shareholders
PRLD price vs earnings per share
PRLD key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $223.2M | $96.7M | $257.7M | $286.1M | $592.6M | $3.13B | — | — |
| Enterprise value | $137.7M | −$18.9M | $41.7M | $86.2M | $303.2M | $2.91B | — | — |
| Price / sales | 18.4 | 13.8 | — | — | — | — | — | — |
| Price / book | 3.3 | 0.7 | 1.1 | 1.5 | 2.1 | 14.7 | — | — |
| EV / sales | 11.3 | -2.7 | — | — | — | — | — | — |
| Earnings yield | −44.6% | −131.6% | −47.3% | −37.5% | −18.7% | −1.8% | — | — |
| Free cash flow yield | −25.3% | −107.2% | −42.9% | −30.3% | −14.5% | −1.5% | — | — |
| Shareholder yield (dividends + buybacks) | — | — | 0.0% | — | — | — | — | — |
| Share price at fiscal year-end | $2.90 | $1.27 | $4.27 | $6.04 | $12.45 | $71.55 | — | — |
| Per share | ||||||||
| Revenue per share | $0.16 | $0.09 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Earnings per share | −$1.29 | −$1.68 | −$2.02 | −$2.27 | −$2.33 | −$1.30 | −$0.85 | — |
| Operating cash flow per share | −$0.73 | −$1.36 | −$1.77 | −$1.77 | −$1.75 | −$1.06 | −$0.79 | — |
| Free cash flow per share | −$0.73 | −$1.37 | −$1.83 | −$1.83 | −$1.80 | −$1.07 | −$0.82 | — |
| Cash per share | $1.34 | $1.76 | $3.86 | $4.26 | $6.12 | $4.99 | $0.58 | — |
| Book value per share | $0.89 | $1.73 | $3.93 | $4.13 | $6.01 | $4.85 | −$1.52 | — |
| Tangible book value per share | $0.89 | $1.73 | $3.93 | $4.13 | $6.01 | $4.85 | −$1.52 | — |
| Capex per share | $0.00 | $0.01 | $0.06 | $0.06 | $0.05 | $0.01 | $0.02 | — |
| Debt per share | $0.23 | $0.24 | $0.28 | $0.04 | $0.04 | — | $0.01 | — |
| Shares outstanding | 77.0M | 75.8M | 60.4M | 47.4M | 47.6M | 43.7M | 32.4M | — |
| Change in shares outstanding | +1.5% | +25.6% | +27.4% | −0.5% | +8.9% | +34.9% | — | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −99.5% | −69.0% | −56.3% | −44.6% | −44.5% | −69.9% | — | — |
| Return on invested capital (ROIC) | — | −598.0% | — | — | — | — | — | — |
| Return on assets (ROA) | −62.8% | −56.1% | −48.9% | −40.8% | −41.9% | −46.4% | −144.1% | −89.5% |
| Return on tangible assets | −70.4% | −72.5% | −43.9% | −48.7% | −36.3% | −25.5% | −126.1% | −89.5% |
| Free cash flow margin | −464.3% | — | — | — | — | — | — | — |
| Financial health | ||||||||
| Total debt | $17.8M | $18.0M | $16.9M | $1.8M | $1.7M | — | $258,000 | — |
| Cash & short-term investments | $103.2M | $133.6M | $232.9M | $201.7M | $291.2M | $218.3M | $18.9M | $15.6M |
| Net debt | −$85.4M | −$115.6M | −$216.0M | −$199.9M | −$289.5M | −$218.3M | −$18.6M | −$15.6M |
| Debt / equity | 0.26 | 0.14 | 0.07 | 0.01 | 0.01 | — | — | — |
| Debt / assets | 0.13 | 0.10 | 0.06 | 0.01 | 0.01 | — | 0.01 | — |
| Current ratio | 1.99 | 5.30 | 10.79 | 9.42 | 15.37 | 19.41 | 4.18 | 6.37 |
| Quick ratio | 1.99 | 5.30 | 10.79 | 9.42 | 15.37 | 19.41 | 4.18 | 6.37 |
| Interest coverage | — | — | — | -93.3 | -55.7 | — | — | — |
| Working capital | $52.7M | $110.3M | $213.8M | $182.7M | $275.9M | $209.4M | $15.4M | $13.1M |
| Invested capital | −$16.8M | $15.9M | $21.0M | −$4.5M | −$3.6M | −$6.1M | −$68.0M | −$38.3M |
| Tangible asset value | $68.6M | $131.5M | $237.1M | $195.4M | $285.9M | $212.2M | −$49.4M | −$22.7M |
| Net current asset value | $33.0M | $91.8M | $195.0M | $179.3M | $275.9M | $209.4M | −$51.1M | −$23.5M |
| Graham net-net per share | $0.40 | $1.18 | $3.19 | $3.73 | $5.71 | $4.73 | −$1.62 | — |
| Capital allocation | ||||||||
| Share buybacks (net) | — | — | $17 | — | — | — | — | — |
| Capex / revenue | 0.6% | 10.9% | — | — | — | — | — | — |
| Capex / depreciation | 0.04 | 0.43 | 3.01 | 2.28 | 2.54 | 1.15 | 2.04 | 3.55 |
| Stock-based compensation / revenue | 98.1% | 304.9% | — | — | — | — | — | — |
| R&D / revenue | 776.8% | 1,685.6% | — | — | — | — | — | — |
| SG&A / revenue | 184.6% | 410.3% | — | — | — | — | — | — |
| Efficiency | ||||||||
| Days payables outstanding | 1,249.6 | 1,268.0 | 1,773.0 | 876.9 | 956.8 | 1,984.6 | 1,593.8 | 3,336.4 |
| Payables turnover | 0.29 | 0.29 | 0.21 | 0.42 | 0.38 | 0.18 | 0.23 | 0.11 |
| Asset turnover | 0.08 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $5.9M | $6.2M | $5.7M | $7.3M | $5.9M | $2.9M | $1.7M | $1.4M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from PRLD's annual financial statements (latest annual report filed March 10, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
PRLD valuation and financial ratios
Prelude Therapeutics earned a return on equity of −99.5% in fiscal 2025. It ended the year with $17.8 million of debt and $103.2 million in cash and short-term investments, a net cash position of $85.4 million.
See the PRLD income statement, the PRLD chart for price history, or the PRLD stock overview for the latest quote and news.
PRLD key metrics FAQ
What is Prelude Therapeutics's return on equity?
Prelude Therapeutics's return on equity (ROE) was −99.5% in fiscal 2025: net income of -$99.5 million on average shareholders' equity of $100.0 million.
How much debt does Prelude Therapeutics have?
Prelude Therapeutics had total debt of $17.8 million at the end of fiscal 2025, a debt-to-equity ratio of 0.26 and more cash than debt.
What is Prelude Therapeutics's free cash flow yield?
Prelude Therapeutics generated -$56.4 million of free cash flow in fiscal 2025, a free cash flow yield of −25.3% on its market value at year-end ($223.2 million).
What is Prelude Therapeutics's current ratio?
Prelude Therapeutics's current ratio was 1.99 at the end of fiscal 2025: current assets were 1.99 times current liabilities.